Medizin
Refine
Year of publication
- 1999 (4) (remove)
Document Type
- Article (4) (remove)
Has Fulltext
- yes (4)
Is part of the Bibliography
- no (4)
Keywords
- Internet (1)
- Internet citation (1)
- Reference (1)
Institute
- Medizin (4)
- Georg-Speyer-Haus (1)
In the late 1980s, laparoscopy was essentially a gynecologist's tool. One of the French private surgeons, Phillipe Mouret of Lyon, shared his surgery practice with a gynecologist and thus had access to both laparoscopic equipment and to patients requiring laparoscopy. In March of 1987, Mouret carried out his first cholecystectomy by means of electronic laparoscopy. Although he never published anything about this experience, the news on his technique reached Francois Dubois of Paris. Although having no prior laparoscopic experience, Dubois acted immediately. He borrowed the instruments from gynecologists, performed his first animal experiments and, in April 1988, carried out the first laparoscopic cholecystectomy (LC) in Paris. Inspired by Dubois, Jacques Perissat of Bordeaux, introduced endoscopic cholecystectomy in his clinic and presented this technique at a SAGES meeting in Louisville in April 1989. Very soon, news of the French work in LC soon swept beyond the country's borders. Dubois and Perissat spoke enthusiastically about their work at the meetings and were largely responsible for establishing what is today called the French technique.
At the end of the 20th century, access to information provided by the World Wide Web (WWW) is changing as never before. The fast availability of current medical literature and the availability of tools for easy access to information, as well as for the easy production of information, have confronted research physicians, scholars, and students with new kinds of problems, many of which concern us personally. Quality control, difficulty establishing basic citation components, lack of standard guidelines for citing, as well as the short lifetime of Internet addresses concern us deeply. Some of these problems could be solved by the concept of an "Online-Library of Medicine" presented in the following paper. Since, however, at the present time there are no good answers to the problems regarding citing Internet-based sources, a Web surfer must keep in his or her mind the motto “caveat lector” (let the reader beware) - or, rather, in the spirit of our time: click c@refully before you cite.
Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture
(1999)
Due to their mode of action, ribozymes show antisense effects in addition to their specific cleavage activity. In the present study we investigated whether a hammerhead ribozyme is capable of cleaving mutated Ki-ras mRNA in a pancreatic carcinoma cell line and whether antisense effects contribute to the activity of the ribozyme. A 2[prime]-O-allyl modified hammerhead ribozyme was designed to cleave specifically the mutated form of the Ki-ras mRNA (GUU motif in codon 12). The activity was monitored by RT-PCR on Ki-ras RNA expression by determination of the relative amount of wild type to mutant Ki-ras mRNA, by 5-bromo-2[prime]-deoxy-uridine incorporation on cell proliferation and by colony formation in soft agar on malignancy in the human pancreatic adenocarcinoma cell line CFPAC-1, which is heterozygous for the Ki-ras mutation. A catalytically inactive ribozyme was used as control to differentiate between antisense and cleavage activity and a ribozyme with random guide sequences as negative control. The catalytically active anti-Ki-ras ribozyme was at least 2-fold more potent in decreasing cellular Ki-ras mRNA levels, inhibiting cell proliferation and colony formation in soft agar than the catalytically inactive ribozyme. The catalytically active anti-Ki-ras ribozyme, but not the catalytically inactive or random ribozyme, increased the ratio of wild type to mutated Ki-ras mRNA in CFPAC-1 cells. In conclusion, both cleavage activity and antisense effects contribute to the activity of the catalytically active anti-Ki-ras hammerhead ribozyme. Specific ribozymes might be useful in the treatment of pancreatic carcinomas containing an oncogenic GTT mutation in codon 12 of the Ki-ras gene.